Related Experiment Videos
An enzyme-linked immunosorbent assay for the Raf/MEK1/MAPK signaling cascade
R Mallon1, L R Feldberg, S C Kim
1Oncology Research, Wyeth-Ayerst Research, 401 North Middletown Road, Pearl River, New York, 10965, USA. mallonr@war.wyeth.com
Analytical Biochemistry
|June 20, 2001
Summary
A new ELISA assay effectively monitors Raf and MEK1 kinase activity, crucial for cancer research. This tool screens compounds for potential cancer therapeutics targeting the Ras-MAPK pathway.
Area of Science:
- Cellular signaling
- Molecular biology
- Cancer research
Background:
- The Ras-MAPK pathway transmits signals for cell growth and proliferation.
- Aberrant Ras activation is implicated in roughly 30% of human cancers.
- Kinase components of this pathway are key targets for cancer drug development.
Purpose of the Study:
- To develop a high-throughput assay for monitoring Raf and MEK1 kinase activity.
- To enable screening of compounds for inhibitors of the Ras-MAPK pathway.
Main Methods:
- Development of a nonradioactive enzyme-linked immunosorbent assay (ELISA).
- Utilized antibodies specific for phosphorylated MAPK to detect kinase activity.
- Assay measures Raf-MEK1 and MEK1-MAPK phosphorylation events.
Main Results:
- The developed ELISA method successfully monitors Raf and MEK1 kinase activity.
- The assay can identify inhibitors targeting Raf and/or MEK1.
- Screened large libraries of random compounds for potential drug candidates.
Conclusions:
- The high-throughput ELISA is a valuable tool for cancer drug discovery.
- The assay facilitates the identification of inhibitors within the Raf/MEK1/MAPK cascade.
- This method aids in targeting the Ras-MAPK pathway for cancer therapy.